ER+ breast cancers with MAPK8 deletions had on average 21.6% lower JNK activity (Fig. 2S), whereas cancers with MAPK9 deletion had 26.9% lower JNK phosphorylation than those without MAPK9 deletions (Fig. 2T). This evidence concerns the gene MAPK9 and breast cancer.